The case report describes a relapse of Crohn's disease in a woman soon after the fitting of a levonorgestrel intrauterine system (IUS) 
Discussion
The 5-year report on clinical performance of the levonorgestrel IUS in a cohort of 678 women, by Cox et al. 2 prompted this case report. In the section reporting 'serious adverse events', it was noted that a 33-year-old woman with a history of CD had been hospitalised with septicaemia 5 days following IUS fitting, though whether the septicaemia was due to the IUS fitting or the CD was debatable. Another woman had an exacerbation of ulcerative colitis (UC) and acne rosacea 25 months after IUS fitting. It is not clear from the report whether these two patients represented the total of all patients in the cohort with pre-existing IBD. However, since the prevalence of CD is in the region of 145 per 100 000, and that of UC 244 per 100 000, this is quite possible. 3 UC and CD are both chronic relapsing disorders. It is not unexpected, therefore, that exacerbations of IBD will occur over time whilst a patient has an IUS in situ, whether or not the device has any effect on the underlying disease process. The practical difficulty will be determining whether abdominal symptoms, particularly if only mild to moderate, are IUS-induced (and should prompt IUS removal) or a part of the natural history of the underlying bowel disorder. A MEDLINE search revealed no references relating specifically to the use of IUS in patients with IBD. In addition, the manufacturers of Mirena ® have received no reports of adverse effects from IUS use in patients with CD (Schering Health Care Ltd, personal communication).
As with the report by Cox, 2 the onset of bowel symptoms after IUS insertion in this patient with previously well-controlled CD gives cause for concern. It was difficult to ascertain whether the physical presence of the device precipitated symptoms, whether it was due to a change in the local hormonal environment, or indeed whether it was coincidental.
There is some evidence that bowel habits are affected by the hormonal environment in the premenstrual and menstrual phase of a cycle, particularly in patients with CD. 1 Whilst current or previous use of combined oral contraception is thought by some to predispose to exacerbations of CD, 4 others, however, disagree 5 (see also CEU Guidance document, page 132).
Clinicians with experience of IUS use in patients with IBD are encouraged to share their experiences so that a more informed picture use can be gained.
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